α9 Integrin and its ligands constitute critical joint microenvironments for development of autoimmune arthritis

Journal of Immunology

Volumn 182, Issue 12, 2009, Pages 8015-8025

  Kanayama, Masashi ^a   Kurotaki, Daisuke ^a   Morimoto, Junko ^a   Asano, Tsuyoshi ^a,b   Matsui, Yutaka ^a   Nakayama, Yosuke ^a   Saito, Yoshinari ^a   Ito, Koyu ^a   Kimura, Chiemi ^a   Iwasaki, Norimasa ^b   Suzuki, Koji ^c   Harada, Tanenobu ^a   Li, Hong Mei ^a   Uehara, Jun ^a   Miyazaki, Tadaaki ^a   Minami, Akio ^b   Kon, Shigeyuki ^a   Uede, Toshimitsu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Hokkaido Orthopedic Memorial Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTEGRIN; ALPHA9 INTEGRIN; ALPHA9 INTEGRIN ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; CYTOKINE; INTEGRIN ALPHA9; LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; DRUG INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; ANIMAL; ARTHRITIS; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL LINE; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; JOINT; METABOLISM; PATHOLOGY;

ANIMALS; ANTIBODIES; ARTHRITIS, EXPERIMENTAL; CELL LINE; CYTOKINES; FIBROBLASTS; IMMUNOTHERAPY; INTEGRIN ALPHA CHAINS; JOINTS; LIGANDS; MACROPHAGES; MICE; MICE, INBRED BALB C;

EID: 67649204689     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900725     Document Type: Article

References (59)

1. Buckley, C. D. 2003. Michael Mason prize essay 2003. Why do leucocytes accumulate within chronically inflamed joints? Rheumatology 42: 1433-1444.
2. Huber, L. C., O. Distler, I. Tarner, R. E. Gay, S. Gay, and T. Pap. 2006. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 45: 669-675.
3. Ruoslahti, E. 1991. Integrins. J. Clin. Invest. 87: 1-5.
4. Hynes, R. O. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25.
5. Bornstein, P., and E. H. Sage. 2002. Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 14: 608-616.
6. Murphy-Ullrich, J. E. 2001. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J. Clin. Invest. 107: 785-790.
7. O'Regan, A., and J. S. Berman. 2000. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int. J. Exp. Pathol. 81: 373-390.
8. Ohshima, S., H. Kobayashi, N. Yamaguchi, K. Nishioka, M. Umeshita-Sasai, T. Mima, S. Nomura, S. Kon, M. Inobe, T. Uede, and Y. Saeki. 2002. Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: possible involvement of osteopontin in bone destruction in arthritis. Arthritis Rheum. 46: 1094-1101.
9. Xu, G., H. Nie, N. Li, W. Zheng, D. Zhang, G. Feng, L. Ni, R. Xu, J. Hong, and J. Z. Zhang. 2005. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J. Clin. Invest. 115: 1060-1067.
10. Chabas, D., S. E. Baranzini, D. Mitchell, C. C. Bernard, S. R. Rittling, D. T. Denhardt, R. A. Sobel, C. Lock, M. Karpuj, R. Pedotti, et al. 2001. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294: 1731-1735.
11. Sato, T., T. Nakai, N. Tamura, S. Okamoto, K. Matsuoka, A. Sakuraba, T. Fukushima, T. Uede, and T. Hibi. 2005. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut 54: 1254-1262.
12. Ashkar, S., G. F. Weber, V. Panoutsakopoulou, M. E. Sanchirico, M. Jansson, S. Zawaideh, S. R. Rittling, D. T. Denhardt, M. J. Glimcher, and H. Cantor. 2000. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287: 860-864.
13. Jansson, M., V. Panoutsakopoulou, J. Baker, L. Klein, and H. Cantor. 2002. Cutting edge: attenuated experimental autoimmune encephalomyelitis in Eta-1/osteopontin-deficient mice. J. Immunol. 168: 2096-2099. (Pubitemid 34171807)
14. Hur, E. M., S. Youssef, M. E. Haws, S. Y. Zhang, R. A. Sobel, and L. Steinman. 2007. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat. Immunol. 8: 74-83.
15. Kitamura, M., K. Iwabuchi, N. Kitaichi, S. Kon, H. Kitamei, K. Namba, K. Yoshida, D. T. Denhardt, S. R. Rittling, S. Ohno, et al. 2007. Osteopontin aggravates experimental autoimmune uveoretinitis in mice. J. Immunol. 178:6567-6572. (Pubitemid 46717440)
16. Petrow, P. K., K. M. Hummel, J. Schedel, J. K. Franz, C. L. Klein, U. Muller-Ladner, J. Kriegsmann, P. L. Chang, C. W. Prince, R. E. Gay, and S. Gay. 2000. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum. 43: 1597-1605.
17. Salter, D. M. 1993. Tenascin is increased in cartilage and synovium from arthritic knees. Br. J. Rheumatol. 32: 780-786.
18. Yumoto, K., M. Ishijima, S. R. Rittling, K. Tsuji, Y. Tsuchiya, S. Kon, A. Nifuji, T. Uede, D. T. Denhardt, and M. Noda. 2002. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc. Natl. Acad. Sci. USA 99: 4556-4561.
19. El-Karef, A., T. Yoshida, E. C. Gabazza, T. Nishioka, H. Inada, T. Sakakura, and K. Imanaka-Yoshida. 2007. Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J. Pathol. 211: 86-94.
20. Diao, H., S. Kon, K. Iwabuchi, C. Kimura, J. Morimoto, D. Ito, T. Segawa, M. Maeda, J. Hamuro, T. Nakayama, et al. 2004. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 21: 539-550.
21. 1 with VCAM-1, tenascin-C, and osteopontin. J. Biol. Chem. 275: 31930-31937.
22. 1 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through interaction with vascular cell adhesion molecule-1. J. Cell Biol. 145: 413-420.
23. 1: a novel osteoclast integrin that regulates osteoclast formation and function. J. Bone Miner. Res. 21: 1657-1665.
24. Yamamoto, N., F. Sakai, S. Kon, J. Morimoto, C. Kimura, H. Yamazaki, I. Okazaki, N. Seki, T. Fujii, and T. Uede. 2003. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J. Clin. Invest. 112: 181-188.
25. Kagari, T., H. Doi, and T. Shimozato. 2002. The importance of IL-1β and TNF-α, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J. Immunol. 169: 1459-1466. (Pubitemid 34809191)
26. Wang, C. T., Y. T. Lin, B. L. Chiang, Y. H. Lin, and S. M. Hou. 2006. High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage 14: 1237-1247.
27. 1 binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J. Biol. Chem. 274: 36328-36334.
28. 1 in the third fibronectin type III repeat of tenascin-C. J. Biol. Chem. 273: 11423-11428.
29. Kon, S., M. Ikesue, C. Kimura, M. Aoki, Y. Nakayama, Y. Saito, D. Kurotaki, H. Diao, Y. Matsui, T. Segawa, et al. 2008. Syndecan-4 protects against osteopontin-mediated acute hepatic injury by masking functional domains of osteopontin. J. Exp. Med. 205: 25-33.
30. 1. Mol. Cell. Biol. 20: 5208-5215.
31. 1 integrin (VLA-4) ligands in arthritis: vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J. Immunol. 149: 1424-1431.
32. Neidhart, M., C. A. Seemayer, K. M. Hummel, B. A. Michel, R. E. Gay, and S. Gay. 2003. Functional characterization of adherent synovial fluid cells in rheumatoid arthritis: destructive potential in vitro and in vivo. Arthritis Rheum. 48: 1873-1880.
33. Ohshima, S., N. Yamaguchi, K. Nishioka, T. Mima, T. Ishii, M. Umeshita-Sasai, H. Kobayashi, M. Shimizu, Y. Katada, S. Wakitani, et al. 2002. Enhanced local production of osteopontin in rheumatoid joints. J. Rheumatol. 29: 2061-2067.
34. Iwakura, Y. 2002. Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine Growth Factor Rev. 13: 341-355.
35. McMurray, R. W. 1996. Adhesion molecules in autoimmune disease. Semin. Arthritis Rheum. 25: 215-233.
36. Yu, Q., and I. Stamenkovic. 2000. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev. 14: 163-176. (Pubitemid 30070982)
37. Schonbeck, U., F. Mach, and P. Libby. 1998. Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing. J. Immunol. 161: 3340-3346. (Pubitemid 128470627)
38. McQuibban, G. A., J. H. Gong, E. M. Tam, C. A. McCulloch, I. Clark-Lewis, and C. M. Overall. 2000. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289: 1202-1206.
39. Itoh, T., H. Matsuda, M. Tanioka, K. Kuwabara, S. Itohara, and R. Suzuki. 2002. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J. Immunol. 169: 2643-2647. (Pubitemid 34921011)
40. Lauffenburger, D. A., and A. F. Horwitz. 1996. Cell migration: a physically integrated molecular process. Cell 84: 359-369.
41. Hemler, M. E., M. J. Elices, C. Parker, and Y. Takada. 1990. Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions. Immunol. Rev. 114: 45-65.
42. 4 integrin antagonists. Curr. Pharm. Des. 8: 1229-1253.
43. Davenport, R. J., and J. R. Munday. 2007. α4-integrin antagonism - an effective approach for the treatment of inflammatory diseases? Drug Discov. Today 12: 569-576.
44. 1 that is widely distributed in epithelia and muscle. J. Cell Biol. 123: 1289-1297.
45. 1 integrin. J. Biol. Chem. 271: 28485-28491.
46. Tanaka, D., T. Kagari, H. Doi, and T. Shimozato. 2006. Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis. Immunology 119: 195-202.
47. Shim, H., S. Oishi, and N. Fujii. 2008. Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors. Semin. Cancer Biol. 19: 123-134.
48. Rollins, B. J. 1997. Chemokines. Blood 90: 909-928.
49. Szekanecz, Z., and A. E. Koch. 2008. Vascular involvement in rheumatic diseases: 'vascular rheumatology.' Arthritis Res. Ther. 10: 224.
50. Li, X., L. Qin, M. Bergenstock, L. M. Bevelock, D. V. Novack, and N. C. Partridge. 2007. Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J. Biol. Chem. 282: 33098-33106.
51. Han, J. H., S. J. Choi, N. Kurihara, M. Koide, Y. Oba, and G. D. Roodman. 2001. Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor B ligand. Blood 97: 3349-3353.
52. Gronthos, S., and A. C. Zannettino. 2007. The role of the chemokine CXCL12 in osteoclastogenesis. Trends Endocrinol. Metab. 18: 108-113.
53. Salmon, M., D. Scheel-Toellner, A. P. Huissoon, D. Pilling, N. Shamsadeen, H. Hyde, A. D. D'Angeac, P. A. Bacon, P. Emery, and A. N. Akbar. 1997. Inhibition of T cell apoptosis in the rheumatoid synovium. J. Clin. Invest. 99: 439-446.
54. Bombara, M. P., D. L. Webb, P. Conrad, C. W. Marlor, T. Sarr, G. E. Ranges, T. M. Aune, J. M. Greve, and M. L. Blue. 1993. Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines. J. Leukocyte Biol. 54: 399-406.
55. Brennan, F. M., and I. B. McInnes. 2008. Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Invest. 118: 3537-3545.
56. Feldmann, M., F. M. Brennan, and R. N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14: 397-440.
57. Horai, R., S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, and Y. Iwakura. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191: 313-320.
58. Noda, M., and G. A. Rodan. 1989. Type β transforming growth factor regulates expression of genes encoding bone matrix proteins. Connect Tissue Res. 21: 71-75.
59. Heino, J., R. A. Ignotz, M. E. Hemler, C. Crouse, and J. Massague. 1989. Regulation of cell adhesion receptors by transforming growth factor-β: concomitant regulation of integrins that share a common β1 subunit. J. Biol. Chem. 264: 380-388.